Skip to main content

Advertisement

Table 1 Clinical manifestation for each patient at baseline a (n = 40)*

From: Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study

Patient/age (yr) Disease duration (mo) Baseline SLEDAI score Baseline BILAG score Total cumulative dose of IS Clinical outcomes after MSCT Clinical manifestations
1/46 40 17 12 CYC 0.8 gm/mo × 28 mo PCR LN, A, C, V, H, ANA+, anti-dsDNA+
2/37 41 12 12 CYC 0.8 gm/mo × 35 mo PCR A, LN, V, ANA+, anti-dsDNA+, H
3/21 50 11 9 MMF 1.5 gm/d × 31 mo NR V, LN, C, anti-SM+
4/28 98 9 9 CYC 0.8 gm/mo × 10 mo, CYC 0.8 gm/mo combined with MMF 1.0 gm/d × 28 mo (discontinue), LEF 20 mg/d × 31 mo MCR V, A, alopecia, LN, C, ANA+, anti-dsDNA+
5/26 120 12 8 MMF 2.0 gm/d × 50 mo (discontinue), CYC 0.8 gm/mo × 20 mo NR V, A, LN, ANA+, anti-dsDNA+
6/23 15 14 19 CYC 0.8 gm/mo × 15 mo, LEF 20 mg/d × 10 mo NR V, A, F, LN, P, ANA+, anti-dsDNA+
7/20 62 12 18 MMF 1.5 gm/d × 34 mo (discontinued), CYC 0.8 gm/mo × 24 mo PCR A, F, LN, C, P, ANA+
8/43 26 34 20 CYC 0.8 gm/mo × 10 mo (discontinued), LEF 20 mg/d × 10 mo PCR → R C, V, LN, A, seizures, ANA+
9/36 97 10 26 CYC 0.8 gm/mo × 29 mo MCR → R C, V, A, LN, P, ANA+
10/39 60 10 7 CYC 0.8 gm/mo × 25 mo (discontinued), LEF 20 mg/d × 30 mo PCR LN, A, V, ANA+, anti-SM+
11/22 40 8 16 CYC 0.8 gm/mo × 25 mo NR LN, C, P, ANA+, anti-dsDNA+
12/20 50 14 13 CYC 0.8 gm/mo × 15 mo (discontinued), VCR 1 mg/week × 4times (discontinued) NR A, severe thrombocytopenia, V, F, ANA+, anti-dsDNA+, anti-SM+
13/17 75 7 6 MMF 1.5 gm/d × 13 mo (discontinued), LEF 20 mg/d × 30 mo NR Severe thrombocytopenia, LN, A, ANA+, anti-dsDNA+
14/21 39 12 11 CYC 0.8 gm/mo × 17 mo NR LN, F, P, A, anti-dsDNA+
15/36 60 10 7 LEF 20 mg/d × 20 mo (discontinued), CYC 0.8 gm/mo × 37 mo MCR LN, V, P, A, ANA+, anti-SM+
16/16 49 11 15 CYC 0.8 gm/mo × 17 mo (discontinued), LEF 20 mg/d × 20 mo NR LN, A, V, ANA+
17/44 145 4 8 CYC 0.8 gm/mo × 64 mo NR LN, A, V, C, ANA+
18/44 85 8 9 CYC 0.8 gm/mo × 40 mo PCR A, LN, F, ANA+, anti-dsDNA+
19/29 86 10 5 CYC 0.8 gm/mo × 24 mo PCR → R LN, A, P, F, ANA+, anti-dsDNA+
20/54 264 8 4 CYC 0.8 gm/mo × 36 mo (discontinued), MMF 1.5 gm/d × 12  mo, then MMF 1.0 gm/d × 28 mo MCR LN, A, V, C, ANA+
21/36 121 13 13 CYC 0.8 gm/mo × 25 mo, LEF 20 mg/d × 40 mo PCR → R LN, A, V, C
22/40 24 12 8 CYC 0.8 gm/mo × 18 mo NR F, V, LN, C, ANA+
23/35 25 14 24 CYC 0.8 gm/mo × 21 mo NR F, A, V, LN, P
24/27 48 12 7 LEF 20 mg/d × 4 mo (discontinued), CYC 0.8 gm/mo × 40 mo MCR LN, F, A, P, ANA+, anti-SM+
25/30 102 10 7 MMF 2.0 gm/d × 6 mo, then tapered to 1.5 gm/d × 36 mo, LEF 20 mg/d × 12 mo, then tapered to 10 mg/d × 59 mo PCR V, A, LN, ANA+, anti-dsDNA+
26/31 62 8 3 MMF 1.5 gm/d × 8 mo, then tapered to 1.0 gm/d × 50 mo, LEF 20 mg/d × 19 mo MCR → R LN, V, P, ANA+, anti-dsDNA+
27/51 108 13 29 CYC 0.8 gm/mo × 41 mo, CsA 150 mg/d × 30 mo NR LN, V, A, C, seizures
28/50 110 10 11 LEF 20 mg/d × 39 mo (discontinued), CYC 0.8 gm/mo × 36 mo MCR A, V, LN, ANA+
29/45 102 10 9 CYC 1.2 gm/mo × 22 mo NR A, V, LN, ANA+, anti-dsDNA+
30/33 62 10 9 CYC 0.8 gm/mo × 21 mo, LEF 20 mg/d × 12 mo MCR LN, A, P, C
31/32 156 14 12 CYC 0.8 gm/mo × 36 mo (discontinued), MMF 1.5 gm/d × 6 mo, then tapered to 1.0 gm/d × 56 mo MCR → R LN, A, C, P
32/53 146 12 10 CYC 0.8 gm/mo × 24 mo, then tapered to 0.6 gm/mo × 42 mo, LEF 20 mg/d × 12 mo, then tapered to 10 mg/d × 40 mo NR LN, A, C, anti-dsDNA+
33/30 157 8 7 CYC 0.8 gm/mo × 16 mo (discontinued) NR V, LN, A, C, H
34/35 123 10 9 CYC 0.8 gm/mo × 18 mo, LEF 20 mg/d × 22 mo NR LN, A, H, C, ANA+
35/33 216 10 3 CYC 0.8 gm/mo × 26 mo PCR F, LN, V, C, A
36/39 99 5 7 CYC 0.8 gm/mo × 14 mo MCR LN, C, V, anti-dsDNA+
37/35 109 6 6 LEF 20 mg/d × 34 mo PCR → R LN, C, H, ANA+
38/31 160 9 7 LEF 20 mg/d × 13 mo (discontinued), CYC 0.8 gm/mo × 35 mo MCR LN, C, V, A
39/50 108 10 12 CYC 0.8 gm/mo × 14 mo MCR F, LN, A, V, C
40/35 96 8 8 CYC 0.8 gm/mo × 28 mo (discontinued), LEF 20 mg/d × 7 mo MCR LN, V, P, C, ANA+
  1. aA, Arthralgia; ANA, Antinuclear antibody; Anti-dsDNA, anti-double-stranded DNA antibody; C, Cytopenia; F, Febrile; H, Hypocomplementemia; IS, Immunosuppressive drug; LN, Lupus nephritis; MCR, Major clinical response; NR, Nonresponse; P, Polyserositis; PCR, Partial clinical response; R, Relapse; V, Vasculitis; VCR, Vincristine. Patients’ clinical manifestations were recorded within 1 week before umbilical cord mesenchymal stem cell transplantation. Total patient population = 40. Patients 1 to 26 were enrolled from the Department of Rheumatology, Affiliated Drum Tower Hospital, Nanjing University Medical School, Nanjing, China. Patients 27 to 32 were enrolled from the Department of Rheumatology, Affiliated Hospital of Jiangsu University, Zhenjiang, China. Patients 33 to 37 were enrolled from the Department of Rheumatology, Subei People’s Hospital of Jiangsu Province, Yangzhou, China. Patients 38 to 40 were enrolled from the Department of Rheumatology, Jiangsu Provincial People’s Hospital, Nanjing, China.